Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform

Table 4 The concordance study between GeneReader, MiSeq, Pyrosequencingand Therascreen PCR assays

Sample no.	KRAS AA change	KRAS variant allele fraction (%)
Sample no.	KRAS AA change	Therascreen PCR/Pyro	GeneReader^a	MiSeq^a
1	G12D	+	21	7
2	G12D	+	39	12
3	A59T	19	15	14
4	G13D	+	41	15
5	G12D	+	45	11
6	Q61H	14	9	13
7	A146P	41	40	32
8	Q61H	36	35	26
9	Q61H	32	22	35
10	K117 N	24	34	39
11	G13D	+	47	15
12	G12C	+	32	10
13	G13D	+	39	10
14	Q61H	26	21	23

+: Variant identified by Therascreen PCR; allele fraction not available
^a: Sample processed from different FFPE section with potentially different tumor content and variant allele fraction

ISSN: 1471-2407